Selvigaltin (GB1211), an orally readily available small molecule galectin-3 inhibitor designed as being a cure for liver fibrosis and cirrhosis, was evaluated to evaluate the impact of hepatic impairment on its pharmacokinetics and protection to deal with regulatory demands. In detail, we utilized the vehicle Manage teams since the calibrator https://selvigaltingb121106825.is-blog.com/46136466/selvigaltin-gb1211-for-dummies